The global psychedelic drugs market is set to skyrocket, reaching $10.2 billion by 2028, driven by increasing awareness of mental health needs, progressive regulatory changes, and the medical community’s growing acceptance of psychedelics for therapeutic applications. This article explores the key drivers, trends, and opportunities shaping this rapidly evolving industry.
A groundbreaking study suggests that low-dose LSD could provide a safe and effective treatment for dogs suffering from separation anxiety. The research, conducted by Spanish scientists, found that a single microdose of LSD significantly reduced anxious behavior in a dog with severe separation anxiety without causing any adverse effects.
A groundbreaking study has shown that LSD can improve social interaction between autistic dogs and their human companions by synchronizing their brainwaves. Researchers observed that the drug enhanced attention and joint attention, key components of social interaction.
A new study reveals that while LSD dosage is a primary driver of its effects, individual differences in mood, personality, and prior psychedelic experience significantly influence the experience. The study underscores the importance of tailoring psychedelic therapies to individual needs.
A recent study published in Heliyon explores the potential therapeutic applications of LSD, revealing its impact on brain regions associated with pain processing. The research, conducted by Hamid Sharini and his team at Kermanshah University of Medical Sciences, utilized fMRI to analyze brain activity in healthy volunteers under the influence of LSD. The findings suggest that LSD alters pain perception by reducing activity in pain-processing regions and disrupting connectivity patterns between brain areas involved in the emotional and cognitive aspects of pain. While promising, further research is needed to understand the long-term implications and potential benefits of LSD for pain management.
